Neoadjuvant Chemotherapy With the Angiogenesis Inhibitor Bevacizumab for Locally Advanced Cervical Cancer.

In Vivo · 2024 · PMC11535958 · PMID 39477433

Europe PMC DOI

hedged sentences

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

did not reach statistical significancep=0.098so close (0.05 < p ≤ 0.1)

Although the results did not meet our goal, our study reaffirmed that pathological complete remission is a statistically significant prognostic factor for PFS (p=0.039), while it did not reach statistical significance for OS (p=0.098).

also in 111,027 other papers

a trend toward significancep=0.098so close (0.05 < p ≤ 0.1)

As shown in Figure 2C, pCR is a statistically significant prognostic factor for PFS (p=0.039), while a trend toward significance was observed for OS (p=0.098).

also in 3,729 other papers

showed a trendno p-value reported

Conclusion While bevacizumab did not demonstrate a significant improvement in overall survival rates, it was associated with a notable reduction in tumor size and showed a trend towards improved clinical response rates.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.